April 22, 2024

bioRN HR Breakfast “Employer branding – Key to high employer attractiveness”

bioRN HR Breakfast “Employer branding – Key to high employer attractiveness”

Employer Branding – Key to high employer attractiveness

The main objectives of employer branding are to increase the general positive perception of the company on the market, to increase employee satisfaction and to attract and retain suitable talent in the long term.
How can SME´s in the life sciences get an employer branding strategy off the ground?

In the workshop you will

  • Receive an introduction to employer branding
  • hear best practices of the employer journey
  • learn more about the Corporate Influencer method 

The workshop is led by the two experts Anna Herb and Leonie Herold from COMMHA Consulting, a
Heidelberg consulting company with a focus on employer branding, change and communication.

About the bioRN Breakfast:

Creativity and a ‘hands-on’ mentality are sometimes essential to tackle the war of talent.  Let’s exchange experiences and benefit from each other! Together we can develop ideas to better overcome the known hurdles. With the HR Breakfast, bioRN aims to promote dialogue between HR managers in the network. Each HR Breakfast has a focal topic, which is determined by the participants in advance. The dialogue takes place in a relaxed atmosphere over coffee, tea and small breakfast treats.

Looking forward to see you there!

register now

Our latest News

discover more
RHEACELL receives EMA approval for allo-APZ2-CVU Phase 3 trial in chronic venous ulcers

RHEACELL receives EMA approval for allo-APZ2-CVU Phase 3 trial in chronic venous ulcers

Heidelberg, Germany, 19.12.2024 – RHEACELL today received approval from the European Medicines Agency (EMA) for its blinded, multi-centric Phase-3 trial (NCT06489028) evaluating allo-APZ2-CVU in patients with chronic venous ulcers (CVU). The pivotal trial will be conducted at more than 100 sites and is expected to enroll 250 patients, starting enrollment in Europe in Q1 2025. […]

Common cough syrup ingredient shows promise in treating serious lung disease

Common cough syrup ingredient shows promise in treating serious lung disease

EMBL scientists discover that an FDA-approved, over-the-counter cough syrup ingredient has potential to treat fibrotic lung disease. Summary A common over-the-counter ingredient in many cough syrups may have a greater purpose for people suffering from lung fibrosis that is related to any number of serious health conditions.  Scientists from EMBL Heidelberg were part of a […]

Antibody that Neutralizes Inhibitory Factors Involved in Nerve Regeneration Leads to Enhanced Motor Function after Acute Spinal Cord Injury

Antibody that Neutralizes Inhibitory Factors Involved in Nerve Regeneration Leads to Enhanced Motor Function after Acute Spinal Cord Injury

Antibodies can improve the rehabilitation of people with acute spinal cord injury. Researchers at 13 clinics in Germany, Switzerland, the Czech Republic and Spain have investigated this with promising results. For the first time, it was possible to identify patient groups that displayed a clinically relevant treatment effect. A follow-up study will start in December […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp